Macroscopic Portal Vein Thrombosis in HCC Patients

Macroscopic portal vein invasion (PVT) by hepatocellular carcinoma (HCC) in the liver is one of the most important negative prognostic factors for HCC patients. The characteristics of a large cohort of such patients were examined. We found that the percent of patients with PVT significantly increased with increasing maximum tumor diameter (MTD), from 13.7% with tumors of MTD <5cm to 56.4% with tumors of MTD >10cm. There were similar numbers of HCC patients with very large tumors with and without PVT. Thus, MTD alone was insufficient to explain the presence of PVT, as were high AFP levels, since less than 50% of high AFP patients had PVT. However, the percent of patients with PVT was also found to significantly increase with increasing blood alpha-fetoprotein (AFP) levels and tumor multifocality. A logistic regression model that included these 3 factors together showed an odds ratio of 17.9 for the combination of MTD>5.0cm plus tumor multifocality plus elevated AFP, compared to low levels of these 3 parameters. The presence or absence of macroscopic PVT may therefore represent different HCC aggressiveness phenotypes, as judged by a significant increase in tumor multifocality and AFP levels in the PVT positive patients. Factors in addition to MTD and AFP must also contribute to PVT development.

[1]  D. Yang,et al.  Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  J. Bruix,et al.  Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.

[3]  B. Carr,et al.  Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients , 2017, The International journal of biological markers.

[4]  J. Marrero,et al.  Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Y. Choi,et al.  Macrovascular invasion is not an absolute contraindication for living donor liver transplantation , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  B. Carr,et al.  Erratum to: Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis , 2016, Digestive Diseases and Sciences.

[7]  K. Boudjema,et al.  Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  B. Carr,et al.  Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis , 2016, Digestive Diseases and Sciences.

[9]  P. Ambrosino,et al.  Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. , 2015, World journal of gastroenterology.

[10]  M. Deng,et al.  Reappraisal of Evidence of Microscopic Portal Vein Involvement by Hepatocellular Carcinoma Cells with Stratification of Tumor Size , 2015, World Journal of Surgery.

[11]  S. Saab,et al.  Management of hepatocellular carcinoma with portal vein thrombosis. , 2015, World journal of gastroenterology.

[12]  C. Sakakura,et al.  Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. , 2015, World journal of gastroenterology.

[13]  Jia-Hui Chu,et al.  Des-γ-Carboxy Prothrombin (DCP) as a Potential Autologous Growth Factor for the Development of Hepatocellular Carcinoma , 2014, Cellular Physiology and Biochemistry.

[14]  J. Lee,et al.  C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion , 2013, World Journal of Surgical Oncology.

[15]  W. Lau,et al.  Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90 , 2013, Oncology.

[16]  S. Ahn,et al.  Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels , 2012, European journal of gastroenterology & hepatology.

[17]  H. Tajiri,et al.  Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma , 2012, Medical Oncology.

[18]  Ziqiu Wang,et al.  Differential Effects of Vitamin K1 on AFP and DCP Levels in Patients with Unresectable HCC and in HCC Cell Lines , 2011, Digestive Diseases and Sciences.

[19]  Zu-hua Gao,et al.  Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway. , 2011, European journal of cancer.

[20]  W. Irish,et al.  Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. , 2010, Hepato-Gastroenterology.

[21]  R. Branch,et al.  Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study , 2010, Hepatology international.

[22]  J. Llovet,et al.  A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. , 2009, Gastroenterology.

[23]  Ming-Hui Chen,et al.  Vitamin K2 Inhibits the Growth of Hepatocellular Carcinoma via Decrease of Des-Gamma-Carboxy Prothrombin , 2008, Chemotherapy.

[24]  A. Vercelli,et al.  Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma , 2008, European Radiology.

[25]  A. Benson,et al.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis , 2007, Hepatology.

[26]  M. Kudo,et al.  Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma , 2007, Journal of Gastroenterology.

[27]  E. Gregoire,et al.  Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series , 2006, Journal of Gastrointestinal Surgery.

[28]  H. Wang,et al.  Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  Y. Shiratori,et al.  Des-γ-carboxy Prothrombin Is a Potential Autologous Growth Factor for Hepatocellular Carcinoma* , 2005, Journal of Biological Chemistry.

[30]  Y. Shiratori,et al.  Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation , 2004, Hepatology.

[31]  R. Tsuchiya,et al.  Prediction of Invasive Activities in Hepatocellular Carcinomas with Special Reference to α-Fetoprotein and Des-γ-carboxyprothrombin , 2003 .

[32]  Y. Shiratori,et al.  Des‐γ‐carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma , 2001, Cancer.

[33]  P. Ferenci,et al.  Hepatocellular carcinoma in Central Europe: prognostic features and survival , 2001, Gut.

[34]  Bernardino,et al.  Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma , 2000, Hepatology.

[35]  M. Tublin,et al.  Benign and malignant portal vein thrombosis: differentiation by CT characteristics. , 1997, AJR. American journal of roentgenology.

[36]  M. Persico,et al.  Ultrasound‐guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: Results in 15 patients , 1995, Journal of gastroenterology and hepatology.

[37]  Ziqiu Wang,et al.  The growth inhibitory effects of vitamins K and their actions on gene expression , 1995, Hepatology.

[38]  K. Sugimachi,et al.  Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. , 1995, Surgery.

[39]  G. Dodd,et al.  Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma. , 1993, AJR. American journal of roentgenology.

[40]  C. Taylor,et al.  Computed tomography in the evaluation of the portal venous system. , 1992, Journal of clinical gastroenterology.

[41]  Dong-hao Wu,et al.  Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma , 2014, Tumor Biology.

[42]  R. Tsuchiya,et al.  Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. , 2003, Japanese journal of clinical oncology.

[43]  Bellia Mario,et al.  Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .

[44]  C. Avellini,et al.  Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study , 1998, Journal of Cancer Research and Clinical Oncology.